Vanda (VNDA) Gets a Hold Rating from Oppenheimer


In a report released yesterday, Esther Rajavelu from Oppenheimer maintained a Hold rating on Vanda (VNDA), with a price target of $21. The company’s shares closed yesterday at $17.31.

Rajavelu observed:

“Ahead of VNDA’s results on 5/1/19, we are updating our model to incorporate updated scripts for Fanapt (per Symphony). Our updated 1Q19 total revenue and adj. EPS are now $53.4M (vs. $53.5M) and $0.08 (vs. $0.09), respectively. We maintain our Perform rating and $21 price target for VNDA.”

According to TipRanks.com, Rajavelu is a 3-star analyst with an average return of 3.0% and a 48.1% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Biohaven Pharmaceutical Holding Co Ltd, and Rocket Pharmaceuticals Inc.

Currently, the analyst consensus on Vanda is a Moderate Buy with an average price target of $35.

See today’s analyst top recommended stocks >>

Based on Vanda’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $10.36 million. In comparison, last year the company had a net profit of $3.07 million.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts